In his current role, Dr. Tarcha is responsible for leading Kineta’s non-clinical and clinical operations. He and his teams are responsible for drug discovery, optimization, in vitro and in vivo pharmacology, toxicology, MOA studies, regulatory and clinical operations. Dr. Tarcha and his team are also responsible for CMC related pharmaceutics operations including drug substance and product development, manufacturing and quality systems.
Dr. Tarcha received his B.S. and M.S. degrees in Medical Technology and Clinical Laboratory Sciences at Michigan State University and earned his PhD in Microbiology and Immunology from the Medical University of Ohio at Toledo. Prior to Kineta, he was a scientist at Illumigen Biosciences leading efforts in assay development, in vivo pharmacology and process development for a novel biologic antiviral therapy.